A Study of DCC-3116 as Monotherapy and Combination Therapy in Patients With MAPK Pathway Mutant Solid Tumors
Enrolling By Invitation
18-99 years
All
Phase
1
380 participants needed
Brief description of study
This is a Phase 1/2, multicenter, open label, study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Mutant Solid Tumors
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male and Female, Age 18 or older Confirmed diagnosis of an advanced or metastatic solid tumor with a documented RAS, NF1, or RAF mutations
Updated on
01 Aug 2024.
Study ID: 849342
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
